Literature DB >> 33467465

Molecular Delivery of Cytotoxic Agents via Integrin Activation.

Martina Cirillo1, Daria Giacomini1.   

Abstract

Integrins are cell adhesion receptors overexpressed in tumor cells. A direct inhibition of integrins was investigated, but the best inhibitors performed poorly in clinical trials. A gained attention towards these receptors arouse because they could be target for a selective transport of cytotoxic agents. Several active-targeting systems have been developed to use integrins as a selective cell entrance for some antitumor agents. The aim of this review paper is to report on the most recent results on covalent conjugates between integrin ligands and antitumor drugs. Cytotoxic drugs thus conjugated through specific linker to integrin ligands, mainly RGD peptides, demonstrated that the covalent conjugates were more selective against tumor cells and hopefully with fewer side effects than the free drugs.

Entities:  

Keywords:  active targeting; cancer; integrins; molecular delivery; receptor targeting; selective citotoxycity

Year:  2021        PMID: 33467465      PMCID: PMC7830197          DOI: 10.3390/cancers13020299

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  115 in total

1.  β-Glucuronidase triggers extracellular MMAE release from an integrin-targeted conjugate.

Authors:  Paula López Rivas; Christoph Müller; Christian Breunig; Torsten Hechler; Andreas Pahl; Daniela Arosio; Laura Belvisi; Luca Pignataro; Alberto Dal Corso; Cesare Gennari
Journal:  Org Biomol Chem       Date:  2019-05-15       Impact factor: 3.876

2.  Novel integrin-targeted binding-triggered drug delivery system for methotrexate.

Authors:  Phanidhara Kotamraj; Wade A Russu; Bhaskara Jasti; Jay Wu; Xiaoling Li
Journal:  Pharm Res       Date:  2011-06-22       Impact factor: 4.200

3.  Mechanism of action of the unusually potent microtubule inhibitor cryptophycin 1.

Authors:  D Panda; R H Himes; R E Moore; L Wilson; M A Jordan
Journal:  Biochemistry       Date:  1997-10-21       Impact factor: 3.162

Review 4.  Metal-organic frameworks and self-assembled supramolecular coordination complexes: comparing and contrasting the design, synthesis, and functionality of metal-organic materials.

Authors:  Timothy R Cook; Yao-Rong Zheng; Peter J Stang
Journal:  Chem Rev       Date:  2012-11-02       Impact factor: 60.622

5.  Targeting the Achilles' heel of cancer cells via integrin-mediated delivery of ROS-generating dihydrolipoamide dehydrogenase.

Authors:  Avraham Dayan; Gideon Fleminger; Osnat Ashur-Fabian
Journal:  Oncogene       Date:  2019-03-14       Impact factor: 9.867

Review 6.  Integrins as Therapeutic Targets: Successes and Cancers.

Authors:  Sabine Raab-Westphal; John F Marshall; Simon L Goodman
Journal:  Cancers (Basel)       Date:  2017-08-23       Impact factor: 6.639

7.  What Is the Fuss about Integrins and the Tumor Microenvironment?

Authors:  Johannes A Eble; Donald Gullberg
Journal:  Cancers (Basel)       Date:  2019-09-03       Impact factor: 6.639

Review 8.  Every step of the way: integrins in cancer progression and metastasis.

Authors:  Hellyeh Hamidi; Johanna Ivaska
Journal:  Nat Rev Cancer       Date:  2018-09       Impact factor: 60.716

9.  Clinical relevance of integrin alpha 4 in gastrointestinal stromal tumours.

Authors:  Olli-Pekka Pulkka; John-Patrick Mpindi; Olli Tynninen; Bengt Nilsson; Olli Kallioniemi; Harri Sihto; Heikki Joensuu
Journal:  J Cell Mol Med       Date:  2018-01-29       Impact factor: 5.310

View more
  2 in total

1.  Selective Integrin Ligands Promote Cell Internalization of the Antineoplastic Agent Fluorouracil.

Authors:  Monica Baiula; Martina Cirillo; Giulia Martelli; Valentina Giraldi; Elisa Gasparini; Alessandro Claudio Anelli; Santi Mario Spampinato; Daria Giacomini
Journal:  ACS Pharmacol Transl Sci       Date:  2021-09-02

Review 2.  Targeting Integrins for Cancer Therapy - Disappointments and Opportunities.

Authors:  Cecilia Bergonzini; Kim Kroese; Annelien J M Zweemer; Erik H J Danen
Journal:  Front Cell Dev Biol       Date:  2022-03-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.